Valion Bio To Carry Out Study At Sheba Medical Center To Mull Entolimod In 10 Cancer Participants
Valion Bio, Inc. (NASDAQ:VBIO) today announced a major clinical development milestone with the finalization of an clinical trial protocol at Sheba Medical Center, one of the world's leading hospitals, to evaluate
Valion Bio is starting a study with a top hospital to test a new medicine called Entolimod on 10 cancer patients. This is an early step to see if the medicine might help, which shows the company is moving forward with its work.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.